News Breaks |
|
|
| August 9, 2012 |
| 07:46 EDT |  | BMY, AZN, AMLN | Bristol-Myers, AstraZeneca complete expansion of diabetes alliance
Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) announced that following the successful completion of the acquisition of Amylin Pharmaceuticals (AMLN) by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2B to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb. As previously disclosed, the payment is being made in connection with the expansion of the diabetes alliance between AstraZeneca and Bristol-Myers Squibb to incorporate the development and marketing of Amylin’s portfolio of diabetes products, and profits and losses arising from the collaboration will be shared equally. AstraZeneca has also informed Bristol-Myers Squibb of its intention to exercise its option to acquire certain additional governance rights over key strategic and financial decisions regarding Amylin’s portfolio. The right to exercise this option will become effective once applicable anti-trust and competition approvals are received by AstraZeneca. Upon the exercise of the option an additional payment of $135M will be made to Bristol-Myers Squibb. |
|
|
News For BMY;AZN;AMLN From The Last 14 Days Check below for free stories on BMY;AZN;AMLN the last two weeks. |
|
|
| May 24, 2013 |
| 16:07 EDT | | AZN | Actavis confirms appeal court issues injunction related to Resupules
Actavis (ACT) confirmed that the United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca (AZN) to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort Respules 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the court. |
|
| 08:22 EDT |  | AZN | Leerink's biotech analysts hold an analyst/industry conference call
 Subscribe for More Information |
|
| May 23, 2013 |
| 06:02 EDT |  | BMY | Bristol-Myers implied volatility at upper end of index mean range
|
|
| 05:47 EDT | | BMY | Stocks with implied volatility movement; SKS BMY
Stocks with implied volatility movement; Saks (SKS), Bristol-Myers (BMY) according to IVolatility. |
|
| May 22, 2013 |
| 16:00 EDT | | BMY | Options Update; May 22, 2013
Subscribe for More Information |
|
| 10:33 EDT | | BMY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
|
| 10:00 EDT |  | BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information |
|
| 06:05 EDT | | BMY | Bristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
| |
| May 21, 2013 |
| 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). |
|
| 07:34 EDT | | BMY | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT | | BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 06:30 EDT |  | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT |  | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT | | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| 10:36 EDT | | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| 08:41 EDT | | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
| |
|
|
|
|
